These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30599818)

  • 1. A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme.
    Garcia Arieta A; Simon C; Lima Santos GM; Calderón Lojero IO; Rodríguez Martínez Z; Rodrigues C; Park SA; Kim JM; Kuribayashi R; Okada Y; Nolting A; Pfäffli C; Hung WY; Crane C; Braddy AC; Van Oudtshoorn J; Gutierrez Triana D; Clarke M
    J Pharm Pharm Sci; 2019; 22(1):28-36. PubMed ID: 30599818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of international regulatory bioequivalence recommendations for approval of generic topical dermatological drug products.
    Braddy AC; Davit BM; Stier EM; Conner DP
    AAPS J; 2015 Jan; 17(1):121-33. PubMed ID: 25344440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Survey of the Criteria Used for the Selection of Alternative Comparator Products by Participating Regulators and Organizations of the International Pharmaceutical Regulators Programme.
    Tam A; Garcia-Arieta A; Abalos I; Agostinho Freitas Fernandes E; Mendes Lima Santos G; Rodriguez Martinez Z; Divinsky M; Kariv R; Potthast H; Braddy AC; Rodrigues C; Guzman Aurela E; Carolina Arevalo Gonzalez L; Gutierres Triana D; Jones B; Ahn C; Kim H; Kim SH; Kuribayashi R; Myoenzono A; Shimojo K; Van Oudtshoorn J; Bigler C; Meincke R; Roost MS; Walther C; Hsu LF; Crane C; Jarman T
    J Pharm Pharm Sci; 2022; 25():323-339. PubMed ID: 36251699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences.
    Davit B; Braddy AC; Conner DP; Yu LX
    AAPS J; 2013 Oct; 15(4):974-90. PubMed ID: 23821352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme.
    Garcia Arieta A; Simon C; Tam A; Mendes Lima Santos G; Freitas Fernandes EA; Rodríguez Martínez Z; Rodrigues C; Park SA; Kim J; Kim K; Kuribayashi R; Myoenzono A; Shimojo K; Walther C; Roost MS; Hung WY; Hsu LF; Crane C; Braddy AC; Van Oudtshoorn J; Gutierrez Triana DA; Guzmán Aurela E; Jones B; Potthast H; Abalos I
    J Pharm Pharm Sci; 2021; 24():113-126. PubMed ID: 33734975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global Harmonization of Comparator Products for Bioequivalence Studies.
    Gwaza L; Gordon J; Leufkens H; Stahl M; García-Arieta A
    AAPS J; 2017 May; 19(3):603-606. PubMed ID: 28265983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities.
    Roost MS; Potthast H; Walther C; García-Arieta A; Abalos I; Agostinho Freitas Fernandes E; Mendes Lima Santos G; Rodríguez Martínez Z; Tam A; Rodrigues C; Gutierrez Triana DA; Guzmán Aurela E; Rodríguez Rodríguez N; Aeh Park S; Kim J; Kariv R; Divinsky M; Jones B; Kuribayashi R; Myoenzono A; Kasuga M; Van Oudtshoorn J; Chi JF; Hung WY; Hsu LF; Crane C; Jarman T; Braddy A
    J Pharm Pharm Sci; 2021; 24():548-562. PubMed ID: 34706215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bioequivalence study design recommendations for immediate-release solid oral dosage forms in the international pharmaceutical regulators programme participating regulators and organisations: differences and commonalities.
    Fernandes EAF; van Oudtshoorn J; Tam A; González LCA; Aurela EG; Potthast H; Mettke K; Kuribayashi R; Shimojo K; Kasuga M; Morales L; Rodríguez Z; Jones B; Ahn C; Yun E; Kim SH; Rodrigues C; Tiong T; Crane C; Walther C; Roost MS; Chen TL; Hsu LF; Braddy AC; García-Arieta A; Abalos I; Divinsky M; Alsuwyeh A; Alzenaidy B; Alharf A
    J Pharm Pharm Sci; 2024; 27():12398. PubMed ID: 38577255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of the international comparator (reference) product system.
    Idänpään-Heikkilä JE
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):36-7. PubMed ID: 11032088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
    Yomota C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
    Kuribayashi R; Yamaguchi T; Takagi K
    Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison.
    Herranz M; Morales-Alcelay S; Corredera-Hernández MT; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C; García-Arieta A
    Eur J Clin Pharmacol; 2013 May; 69(5):1157-62. PubMed ID: 23196824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system.
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme.
    Van Oudtshoorn JE; García-Arieta A; Santos GML; Crane C; Rodrigues C; Simon C; Kim JM; Park SA; Okada Y; Kuribayashi R; Pfäffli C; Nolting A; Lojero IOC; Martínez ZR; Hung WY; Braddy AC; Leal NA; Triana DG; Clarke M; Bachmann P
    J Pharm Pharm Sci; 2018; 21(1):27-37. PubMed ID: 29382433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.